Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

LNTH vs RMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.61B
5Y Perf.+527.5%
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.54B
5Y Perf.+30.4%

LNTH vs RMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LNTH logoLNTH
RMD logoRMD
IndustryDrug Manufacturers - Specialty & GenericMedical - Instruments & Supplies
Market Cap$5.61B$30.54B
Revenue (TTM)$1.54B$5.54B
Net Income (TTM)$234M$1.52B
Gross Margin61.1%61.7%
Operating Margin20.2%34.3%
Forward P/E16.6x19.0x
Total Debt$738K$852M
Cash & Equiv.$359M$1.21B

LNTH vs RMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LNTH
RMD
StockMay 20May 26Return
Lantheus Holdings, … (LNTH)100627.5+527.5%
ResMed Inc. (RMD)100130.4+30.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: LNTH vs RMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RMD leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Lantheus Holdings, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LNTH
Lantheus Holdings, Inc.
The Income Pick

LNTH is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 0 yrs, beta 0.47
  • 40.0% 10Y total return vs RMD's 301.1%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
Best for: income & stability and long-term compounding
RMD
ResMed Inc.
The Growth Play

RMD carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 9.8%, EPS growth 37.4%, 3Y rev CAGR 12.9%
  • 9.8% revenue growth vs LNTH's 0.5%
  • 27.4% margin vs LNTH's 15.2%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthRMD logoRMD9.8% revenue growth vs LNTH's 0.5%
ValueLNTH logoLNTHLower P/E (16.6x vs 19.0x)
Quality / MarginsRMD logoRMD27.4% margin vs LNTH's 15.2%
Stability / SafetyLNTH logoLNTHBeta 0.47 vs RMD's 0.66, lower leverage
DividendsRMD logoRMD1.0% yield; 14-year raise streak; the other pay no meaningful dividend
Momentum (1Y)RMD logoRMD-12.4% vs LNTH's -17.8%
Efficiency (ROA)RMD logoRMD18.0% ROA vs LNTH's 10.8%, ROIC 22.8% vs 30.6%

LNTH vs RMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M

LNTH vs RMD — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLRMDLAGGINGLNTH

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 5 of 6 comparable metrics.

RMD is the larger business by revenue, generating $5.5B annually — 3.6x LNTH's $1.5B. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to LNTH's 15.2%. On growth, RMD holds the edge at +10.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
RevenueTrailing 12 months$1.5B$5.5B
EBITDAEarnings before interest/tax$381M$2.1B
Net IncomeAfter-tax profit$234M$1.5B
Free Cash FlowCash after capex$349M$1.8B
Gross MarginGross profit ÷ Revenue+61.1%+61.7%
Operating MarginEBIT ÷ Revenue+20.2%+34.3%
Net MarginNet income ÷ Revenue+15.2%+27.4%
FCF MarginFCF ÷ Revenue+22.6%+31.7%
Rev. Growth (YoY)Latest quarter vs prior year+4.0%+10.8%
EPS Growth (YoY)Latest quarter vs prior year+5.8%+9.3%
RMD leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

LNTH leads this category, winning 4 of 6 comparable metrics.

At 22.0x trailing earnings, RMD trades at a 13% valuation discount to LNTH's 25.3x P/E. On an enterprise value basis, LNTH's 13.8x EV/EBITDA is more attractive than RMD's 15.7x.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
Market CapShares × price$5.6B$30.5B
Enterprise ValueMkt cap + debt − cash$5.3B$30.2B
Trailing P/EPrice ÷ TTM EPS25.26x22.04x
Forward P/EPrice ÷ next-FY EPS est.16.59x19.03x
PEG RatioP/E ÷ EPS growth rate1.27x
EV / EBITDAEnterprise value multiple13.78x15.71x
Price / SalesMarket cap ÷ Revenue3.64x5.93x
Price / BookPrice ÷ Book value/share5.41x5.18x
Price / FCFMarket cap ÷ FCF15.84x18.38x
LNTH leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

RMD leads this category, winning 5 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $21 for LNTH. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RMD's 0.14x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs LNTH's 5/9, reflecting strong financial health.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
ROE (TTM)Return on equity+20.6%+24.4%
ROA (TTM)Return on assets+10.8%+18.0%
ROICReturn on invested capital+30.6%+22.8%
ROCEReturn on capital employed+17.1%+25.7%
Piotroski ScoreFundamental quality 0–958
Debt / EquityFinancial leverage0.00x0.14x
Net DebtTotal debt minus cash-$358M-$358M
Cash & Equiv.Liquid assets$359M$1.2B
Total DebtShort + long-term debt$738,000$852M
Interest CoverageEBIT ÷ Interest expense16.89x66.06x
RMD leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — LNTH and RMD each lead in 3 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $39,000 today (with dividends reinvested), compared to $11,357 for RMD. Over the past 12 months, RMD leads with a -12.4% total return vs LNTH's -17.8%. The 3-year compound annual growth rate (CAGR) favors RMD at -2.5% vs LNTH's -3.1% — a key indicator of consistent wealth creation.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
YTD ReturnYear-to-date+28.1%-14.1%
1-Year ReturnPast 12 months-17.8%-12.4%
3-Year ReturnCumulative with dividends-9.1%-7.2%
5-Year ReturnCumulative with dividends+290.0%+13.6%
10-Year ReturnCumulative with dividends+4002.4%+301.1%
CAGR (3Y)Annualised 3-year return-3.1%-2.5%
Evenly matched — LNTH and RMD each lead in 3 of 6 comparable metrics.

Risk & Volatility

LNTH leads this category, winning 2 of 2 comparable metrics.

LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than RMD's 0.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 79.1% from its 52-week high vs RMD's 71.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
Beta (5Y)Sensitivity to S&P 5000.47x0.66x
52-Week HighHighest price in past year$108.91$293.81
52-Week LowLowest price in past year$47.25$198.64
% of 52W HighCurrent price vs 52-week peak+79.1%+71.4%
RSI (14)Momentum oscillator 0–10060.532.7
Avg Volume (50D)Average daily shares traded878K1.1M
LNTH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

RMD leads this category, winning 1 of 1 comparable metric.

Wall Street rates LNTH as "Buy" and RMD as "Buy". Consensus price targets imply 34.2% upside for RMD (target: $281) vs 17.2% for LNTH (target: $101). RMD is the only dividend payer here at 1.01% yield — a key consideration for income-focused portfolios.

MetricLNTH logoLNTHLantheus Holdings…RMD logoRMDResMed Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$101.00$281.29
# AnalystsCovering analysts1735
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises014
Dividend / ShareAnnual DPS$2.11
Buyback YieldShare repurchases ÷ mkt cap+5.3%+1.0%
RMD leads this category, winning 1 of 1 comparable metric.
Key Takeaway

RMD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LNTH leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.

Best OverallResMed Inc. (RMD)Leads 3 of 6 categories
Loading custom metrics...

LNTH vs RMD: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is LNTH or RMD a better buy right now?

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). ResMed Inc. (RMD) offers the better valuation at 22. 0x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LNTH or RMD?

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 22. 0x versus Lantheus Holdings, Inc. at 25. 3x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 16. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — LNTH or RMD?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +290. 0%, compared to +13. 6% for ResMed Inc. (RMD). Over 10 years, the gap is even starker: LNTH returned +40. 0% versus RMD's +301. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LNTH or RMD?

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus ResMed Inc. 's 0. 66β — meaning RMD is approximately 40% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 14% for ResMed Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — LNTH or RMD?

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: ResMed Inc. grew EPS 37. 4% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LNTH or RMD?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 15. 2% for Lantheus Holdings, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 20. 2% for LNTH. At the gross margin level — before operating expenses — LNTH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LNTH or RMD more undervalued right now?

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 16. 6x forward P/E versus 19. 0x for ResMed Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RMD: 34. 2% to $281. 29.

08

Which pays a better dividend — LNTH or RMD?

In this comparison, RMD (1.

0% yield) pays a dividend. LNTH does not pay a meaningful dividend and should not be held primarily for income.

09

Is LNTH or RMD better for a retirement portfolio?

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +301. 1% 10Y return). Both have compounded well over 10 years (RMD: +301. 1%, LNTH: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LNTH and RMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RMD pays a dividend while LNTH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 9%
Run This Screen
Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LNTH and RMD on the metrics below

Revenue Growth>
%
(LNTH: 4.0% · RMD: 10.8%)
Net Margin>
%
(LNTH: 15.2% · RMD: 27.4%)
P/E Ratio<
x
(LNTH: 25.3x · RMD: 22.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.